Study of Zoldonrasib + Chemo of Investigator’s Choice vs Placebo + Chemo of Investigator’s Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

by | Jun 2, 2026 | Clinical Trials | 0 comments

​ Conditions: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC – Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma

Interventions: Drug: Zoldonrasib; Drug: Placebo; Drug: Oxaliplatin; Drug: Leucovorin (Calcium Folinate); Drug: 5-Fluorouracil; Drug: Irinotecan; Drug: Gemcitabine (GEM); Drug: Nab-paclitaxel

Sponsors: Revolution Medicines, Inc.

Recruiting Conditions: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC – Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma
Interventions: Drug: Zoldonrasib; Drug: Placebo; Drug: Oxaliplatin; Drug: Leucovorin (Calcium Folinate); Drug: 5-Fluorouracil; Drug: Irinotecan; Drug: Gemcitabine (GEM); Drug: Nab-paclitaxel
Sponsors: Revolution Medicines, Inc.
Recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *